LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Kodu・Aktsiate loetelu・Cogent Biosciences Inc

Cogent Biosciences Inc

Suletud

35.68 5.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

37.06

Põhinäitajad
By Trading Economics
Sissetulek	-22M -102M
Aktsiakasum	-0.5
Töötajad	258
EBITDA	-30M -109M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+54.56% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	399M 6B
Eelmine avamishind	30.37
Eelmine sulgemishind	35.68

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

4.88 / 5.87 Toetus ja vastupanu

Cogent Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15. märts 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15. märts 2026, 23:45 UTC

Market Talk

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15. märts 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15. märts 2026, 22:37 UTC

Market Talk

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15. märts 2026, 22:18 UTC

Market Talk

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15. märts 2026, 22:14 UTC

Tulu

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 22:00 UTC

Uudisväärsed sündmused

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15. märts 2026, 03:00 UTC

Uudisväärsed sündmused

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Iran War Delivers Windfall to America's Oil Country -- WSJ

14. märts 2026, 02:03 UTC

Tulu

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14. märts 2026, 01:32 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14. märts 2026, 00:29 UTC

Omandamised, ülevõtmised, äriostud

13D Filings -- Barrons.com

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cogent Biosciences Inc Prognoos

Hinnasiht

By TipRanks

54.56% tõus

12 kuu keskmine prognoos

Keskmine 52.55 USD 54.56%

Kõrge 64 USD

Madal 35 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Cogent Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.88 / 5.87Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.